Shields Health Solutions argues dropout is a support gap, citing its pharmacist-led program where only 19.7% quit at one year.
Recap by typeshit. Full story at The American Journal of Managed Care.
A short Facebook share with no context on who used the peptides, where it happened or what followed.
Benzinga notes a 1.89% after-hours gain for Lilly stock, with Novo Nordisk also tagged. No further detail on what drove the move.
Mikhail Varshavski tells Fox News why protein matters, especially for GLP-1 users. He has a paid partnership with Quest Nutrition.
2:07:50
A live Q&A session covering GLP-1 drugs including Zepbound, Wegovy and Foundayo, with the host taking questions from viewers.
Medical Xpress covers work on blocking an enzyme in fat cells, framed against US adult obesity rates above 40% between 2021 and 2023.
Bikman cites a four-week trial in young men eating about 40% under their needs, where the high-protein group added lean mass and shed more fat.
Loading…